Piper Sandler cuts Stryker stock price target on Q3 miss

Stryker’s Q3 2026 revenue was $6.52B versus $6.62B consensus, and EPS of $3.52 missed expectations by $0.03; the company also lowered full-year guidance. Piper Sandler cut its price target to $325 from $390 but maintained an Overweight rating, citing weakness in the large joint market and anticipating a high-single-digit share decline. The firm views the market slowdown as temporary, expects recovery in 2027, and projects 6%–7% revenue growth going forward.

Analysis

Core read: The risk is less the quarterly miss than the mechanism behind it: higher patient cost-sharing and denial friction can defer elective joint procedures, shifting revenue across quarters and making near-term estimates less reliable. If denial rates reflect broader payer behavior rather than a temporary deductible-season effect, the market may be underestimating the duration of the slowdown. Conversely, a volume pause does not by itself establish a lasting loss of share or product competitiveness.

Relative winners/losers: Zimmer Biomet, Smith+Nephew and Johnson & Johnson’s orthopedics businesses face similar procedure and reimbursement exposure; do not assume they gain share unless procedure data show Stryker-specific weakness. More diversified medtech businesses may hold up relatively better if investors rotate away from elective-orthopedics sensitivity, but a sector-wide slowdown would limit that hedge.

Horizon and contrarian view: In the next 1–3 months, estimate revisions and evidence on large-joint volumes/denials matter more than analyst target changes. Over 6–18 months, product launches and any normalization in access could support recovery, but that is conditional—not yet demonstrated. The contrarian risk is that the selloff over-discounts a temporary access issue; the counterpoint is that an “undervalued” screen and a 2027 recovery expectation are not evidence that estimates have troughed. Further guidance cuts would invalidate the temporary-disruption thesis.

Key Decisions for Investors

• No immediate outright short: negative revisions are already widespread, while the duration of the procedure/access issue is unverified. Keep SYK at neutral/underweight rather than adding on valuation alone.
• Set an alert for the next earnings update and independent large-joint procedure, denial-rate, and payer-access indicators. A further guidance reduction or continued deterioration in volumes would support a tactical short; stable volumes and improving access would argue against it.
• Avoid treating ZBH or Smith+Nephew as automatic longs against SYK: first compare their joint-procedure trends and guidance to distinguish market-wide weakness from company-specific execution.
• Reassess the 6–18 month recovery case against order/volume trends and launch contribution; if management’s recovery timing slips, reduce exposure rather than relying on analyst price targets.